Ortega E, Barrón BL

Language: Spanish
References: 30
Page: 9-15
PDF size: 270.12 Kb.

ABSTRACT

The hemorrhagic fever caused by Ebola virus is a disease with high mortality, mainly reported in Africa, with 24 outbreaks until now. Currently, the biggest and geographically extended outbreak is ongoing. The occurrence of some cases in United States and Spain, means a big alert for health officers among the world. The risk of an outbreak in Mexico is minimum, however it could be useful to survey the possibility of imported cases. This work reviews the characteristics of this outbreak and its implications in our country.

REFERENCES

1. Feldmann H, Sanchez A, Geisbert TW. Filoviridae: Marburg and Ebola viruses. In: Knipe DM, Howley PM. Fields virology. 6 ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2013: pp. 923-956.

2. Viral zone: Ebola virus molecular biology. Suiza: 2014. [Enero de 2015]. Disponible en: http://www.viralzone.expasy.org

3. Alvarez CP, Lasala F, Carrillo J, Muñiz O, Corbí AL, Delgado R. C-type lectins DC-SING and L-SING mediate cellular entry by Ebola virus in cis and in trans. J Virol. 2002; 67: 6841-6844.

4. Nanbo A, Masaki I, Watanabe S, Noda T, Takahashi K, Neumann G et al. Ebolavirus is internalized into host cells via micropinocytosis in a viral glycoprotein-dependent manner. PLoS Pathog. 2010; 6: e1001121.

5. Leroy EM, Kumulungui B, Pourrut X, Rouquet P, Hassanin A, Yaba P et al. Fruit bats as reservoirs of Ebola virus. Nature. 2005; 438: 575-576.

6. Bausch DG, Towner JS, Dowell SF, Kaducu F, Lukwiya, Sanchez A. Assessment of the risk of Ebola virus transmission from bodily fluids and fomites. J Infectious Dis. 2007; 196: S12-147.

7. Ströher U, West E, Bugany H, Klenk HD, Schnittler HJ et al. Infection and activation of monocytes by Marburg and Ebola viruses. J Virol. 2001; 75: 11025-11033.

8. Martines RB, Ng DL, Greer PW, Rollin PE, Zaki SR. Tissue and cellular tropism, pathology and pathogenesis of Ebola and Marburg viruses. J Pathol. 2014; 235: 153-174. doi: 10.1002/path.4456.

9. Bente D, Gren J, Strong JE, Feldmann H. Disease modeling for Ebola and Marburg diseases. Disease Models and Mechanisms. 2009; 2: 12-17.

10. Kortepetern MK, Bausch DG, Bray M. Basic clinical and laboratory features of filoviral hemorrhagic fever. J Infectious Diseases. 2011; 204: S810-S816.

11. Beize S, Pannetier D, Pharm D, Oestereich L, Rieger T, Koivogui L et al. Emergence of Zaire Ebola virus disease in guinea. N Egl J Med. 2014; 371: 1418-1425.

12. Gire SK, Goba A, Andersen KG, Sealfon RSG, Park DJ, Kanneh L et al. Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science. 2014; 345: 1369-1372.

13. World Health Organization. Ebola response roadmap situation report. [5 de abril 2015]. Disponible en: http://www.who.int/csr/disease/ebola/situation-reports/en/

14. Chan M. Ebola virus diseases in west Africa-no early end to the outbreak. N Engl J Med. 2014; 371: 1183-1185.

15. Wesolowski A, Buckee CO, Bengtsson L, Wetter E, Lu X, Tatem AJ. Commentary: containing the Ebola outbreak-the potential and challenge of mobile network data. PLoS Curr. 2014; doi: 10.1371/currents.outbreaks.0177e7fcf52217b8b634376e2f3efc5e.

16. Frieden TR, Damon I, Bell BP, Kenyon T, Nichol S. Ebola 2014-new challenges, new global response and responsibility. 2014; 371: 1177-1180.

17. Philips M, Markham A. Ebola: a failure of international collective action. The Lancet. 2014; 384: 1181.

18. Dudas G, Rambaut A. Phylogenetic analysis of guinea 2014 EBOV Ebolavirus outbreak. PLoS Curr. 2014; doi: 10.1371/currents.outbreaks.84eefe5ce43ec9dc0bf0670f7b8b417d.

19. Centers for Disease Control and Prevention. 2014 Ebola outbreak in Democratic Republic of the Congo. [Enero 2015]. Disponible en: http://www.cdc.gov/vhf/ebola/outbreaks/drc/2014-august.html

20. Leroy EM, Labouba I, Maganga GD, Berthet N. Ebola in West Africa: the outbreak able to change many things. Clin Microbiol Infect. 2014; doi: 10.1111/1469-0691.12781.

21. Gulland A. More health staff are needed to contain Ebola outbreak, warns WHO. BMJ. 2014; 349: g5485.

22. Rivers CM, Lofgren ET, Marathe M, Eubank S, Lewis BL. Modeling the Impact of Interventions on an Epidemic of Ebola in Sierra Leone and Liberia. PLoS Curr. 2014; doi: 10.1371/currents.outbreaks.fd38dd85078565450b0be3fcd78f5ccf

23. Hampton T. Largest-ever outbreak of Ebola virus disease thrusts experimental therapies, vaccines into spotlight. JAMA. 2014; 312: 987-989.

24. Pettitt J, Zeitlin L, Kim DH, Working C, Johnson JC, Bohorov O et al. Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. Sci Transl Med. 2013; 199: 199ra113.

25. Geisbert TW, Lee ACH, Robbins M, Geisbert JB, Honko AN, Sood V et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet. 2010; 375: 1896-1905.

26. Dirección General de Epidemiología de la Secretaría de Salud. Lineamientos estandarizados para la vigilancia epidemiológica y diagnóstico por laboratorio de enfermedad por el virus del Ébola. 2014.

27. WHO. Technical specifications for PPE equipment to be used by health workers providing clinical care for patients. Disponible en: http://apps.who.int/iris/bitstream/10665/137411/1/WHO_EVD_Guidance_SpecPPE_14.1_eng.pdf?ua=1.

28. Feldmann H, Jones SM, Daddario-DiCaprio KM, Giesbert JB, Ströher U, Grolla A et al. Effective post-exposure treatment of Ebola infection. PloS Pathog. 2007; 3 (1): e2.

29. Warren TK, Wells J, Panchal RG, Stuthman KS, Garza NL, van Tongeren SA et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature. 2014; 508: 402-405.

30. Geisbert TW, Bailey M, Hensley L, Asiedu C, Geisbert J, Stanley D et al. Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge. J Virol. 2011; 85: 4222-4233.